Sugi Predict

Sugi Predict / Compounds / SCHEMBL259605

SCHEMBL259605

SCHEMBL259605

COC(=O)c1sccc1NC(=O)c1cccc(OC)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 1.00
▸ HPGD P15428 5/20 0.78
▸ POLB P06746 4/20 0.78
▸ SMN1; SMN2 Q16637 3/20 0.78
▸ L3MBTL1 Q9Y468 2/20 0.73
▸ ALDH1A1 P00352 5/20 0.71
▸ KDM4E B2RXH2 3/20 0.71
▸ MAPK10 P53779 3/20 0.71
▸ LMNA P02545 1/20 0.71
▸ NPSR1 Q6W5P4 1/20 0.71
▸ TDP1 Q9NUW8 1/20 0.67
▸ KMT2A Q03164 4/20 0.66
▸ MEN1 O00255 3/20 0.66
▸ NPC1 O15118 1/20 0.64
▸ RAB9A P51151 1/20 0.64
▸ TSHR P16473 1/20 0.63
▸ NLRP1 Q9C000 1/20 0.63
▸ RXFP1 Q9HBX9 1/20 0.63
▸ MAPK1 P28482 1/20 0.62
▸ HSD17B10 Q99714 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29397956 1.00 MAPT (1.00) MAPTHPGDPOLBSMN1; SMN2L3MBTL1
SCHEMBL258546 0.90 MAPT (0.81) MAPTHPGDPOLBSMN1; SMN2L3MBTL1
SCHEMBL14104057 0.87 MAPT (0.77) MAPTHPGDPOLBSMN1; SMN2L3MBTL1
SCHEMBL22287878 0.86 MAPT (0.76) MAPTHPGDPOLBSMN1; SMN2L3MBTL1
SCHEMBL9070025 0.85 L3MBTL1 (1.00) MAPTHPGDPOLBSMN1; SMN2L3MBTL1
SCHEMBL17859663 0.85 MAPT (0.73) MAPTHPGDPOLBSMN1; SMN2L3MBTL1
SCHEMBL274082 0.82 MAPT (0.70) MAPTHPGDPOLBSMN1; SMN2L3MBTL1
SCHEMBL25311259 0.81 MAPT (0.67) MAPTHPGDPOLBSMN1; SMN2L3MBTL1
SCHEMBL11246385 0.80 MEN1 (1.00) MAPTPOLBSMN1; SMN2ALDH1A1KDM4E
SCHEMBL14104058 0.79 KMT2A (0.70) MAPTHPGDPOLBSMN1; SMN2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12522614-B2 Topical phosphoinositide 3-kinase inhibitors VENTHERA, INC. (US) 2026-01-13 — — US disclosed
US-20230416269-A1 TOPICAL PHOSPHOINOSITIDE 3-KINASE INHIBITORS COA THERAPEUTICS, INC. 2023-12-28 — — US disclosed
US-11661429-B2 Topical phosphoinositide 3-kinase inhibitors VENTHERA, INC. (US) 2023-05-30 — — US disclosed
US-11661429-B2 Topical phosphoinositide 3-kinase inhibitors VENTHERA, INC. (US) 2023-05-30 — — US disclosed
US-11661429-B2 Topical phosphoinositide 3-kinase inhibitors VENTHERA, INC. (US) 2023-05-30 — — US disclosed
CN-114072144-A External phosphoinositide 3-kinase inhibitors 维瑟拉有限公司 2022-02-18 — — CN disclosed
EP-3920911-A1 TOPICAL PHOSPHOINOSITIDE 3-KINASE INHIBITORS Venthera, Inc. (US) 2021-12-15 — — EP disclosed
WO-2020163525-A1 TOPICAL PHOSPHOINOSITIDE 3-KINASE INHIBITORS VENTHERA, INC. (US) 2020-08-13 — — WO disclosed
WO-2020163525-A1 TOPICAL PHOSPHOINOSITIDE 3-KINASE INHIBITORS VENTHERA, INC. (US) 2020-08-13 — — WO disclosed
US-20200247816-A1 TOPICAL PHOSPHOINOSITIDE 3-KINASE INHIBITORS NAVIRE PHARMA, INC. 2020-08-06 — — US disclosed
EP-2035431-A1 PHARMACEUTICAL COMPOUNDS F.HOFFMANN-LA ROCHE AG (CH) 2009-03-18 — — EP disclosed
US-20080207609-A1 Pharmaceutical compounds PLRAMED LIMITED (GB) 2008-08-28 — — US disclosed
US-20080207609-A1 Pharmaceutical compounds PLRAMED LIMITED (GB) 2008-08-28 — — US disclosed
US-20080207609-A1 Pharmaceutical compounds PLRAMED LIMITED (GB) 2008-08-28 — — US disclosed
WO-2007132171-A1 PHARMACEUTICAL COMPOUNDS F.HOFFMANN-LA ROCHE AG (CH) 2007-11-22 — — WO disclosed
EP-1812446-A1 PHARMACEUTICAL COMPOUNDS Piramed Limited (GB) 2007-08-01 — — EP disclosed
US-20070037805-A1 Fused heteroaryl derivatives HAYAKAWA MASAHIKO 2007-02-15 — — US disclosed
US-7173029-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2007-02-06 — — US disclosed
US-7173029-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2007-02-06 — — US disclosed
WO-2006046040-A1 PHARMACEUTICAL COMPOUNDS PIRAMED LIMITED (GB) 2006-05-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200247816-A1 TOPICAL PHOSPHOINOSITIDE 3-KINASE INHIBITORS PIK3C3, PIK3CA, PIK3R1 MAPT 4326/4885HPGD 4035/4885POLB 950/4885
US-20070037805-A1 Fused heteroaryl derivatives PIK3CD, PIK3R3, PIK3C2A MAPT 3923/4885HPGD 4466/4885POLB 2203/4885
US-11661429-B2 Topical phosphoinositide 3-kinase inhibitors PIK3C3, PIK3CA, PIK3R1 MAPT 4326/4885HPGD 4035/4885POLB 950/4885
US-20230416269-A1 TOPICAL PHOSPHOINOSITIDE 3-KINASE INHIBITORS PIK3C3, PIK3CA, PIK3R1 MAPT 4326/4885HPGD 4035/4885POLB 950/4885
US-20080207609-A1 Pharmaceutical compounds PIK3CA, JAK2, PIK3R1 MAPT 2811/4885HPGD 3691/4885POLB 1154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.